AnaptysBio's Royalty Model Delivers Again, But the Real Verdict Remains With the Court

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

AnaptysBio typically reports earnings after market close, meaning Day 0 reflects anticipation before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior shows moderate volatility around earnings events, with an average absolute Day 0 move of 3.10% and Day 0 range of 5.67%. The Day +1 reaction is notably larger, averaging 7.07% with a range of 14.17%, indicating that the market's full assessment often takes a full trading session to materialize.

The most recent earnings release on May 12, 2026, saw the stock decline 3.45% on Day 0 with a range of 8.61%, followed by a 4.41% decline on Day +1 with an 11.06% range. The March 2026 report produced the most dramatic reaction, with a modest 3.79% Day 0 decline followed by a powerful 14.61% Day +1 surge and 16.12% range as investors digested the separation-related results.

Earlier reports showed more muted reactions, with the November 2024 release producing an 11.72% Day +1 gain and the August 2025 report generating a 9.63% Day +1 decline. The pattern suggests investors should prepare for meaningful post-earnings volatility, particularly on the day following the release, with moves frequently exceeding 10% as the market processes both the quarterly results and any updates on the GSK litigation.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 9.31% (approximately $5.02) for the October 16, 2026 expiration, which is higher than the average historical Day 0 move of 3.10% but consistent with the average Day +1 move of 7.07%. This suggests options traders are anticipating above-average volatility, likely reflecting uncertainty around both the quarterly results and potential news on the GSK litigation that could emerge before expiration.

Part 3: What Analysts Are Saying

Analyst sentiment remains strongly bullish on AnaptysBio, with the current consensus showing 10 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings among 11 analysts covering the stock. The average recommendation of 4.82 sits firmly in Strong Buy territory, reflecting high conviction despite near-term uncertainties.

The average price target of $86.80 implies 61% upside from the current price of $53.92, with estimates ranging from a low of $70.00 to a high of $140.00. This wide range reflects differing views on the potential outcome of the GSK litigation and the long-term value of the Jemperli royalty stream.

Sentiment has deteriorated slightly over the past month, with Strong Buy ratings declining from 11 to 10. This modest pullback likely reflects analyst caution as the market awaits the court ruling rather than fundamental concerns about the business. The overwhelming bullish consensus suggests analysts view the current price as an attractive entry point, particularly if the litigation resolves favorably or if Jemperli's commercial momentum continues to accelerate with potential label expansions.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a Buy signal at 8%, representing a significant shift from last week's Sell signal at 8% and a substantial decline from last month's Buy signal at 40%. This deterioration reflects weakening technical momentum as the stock has drifted lower heading into earnings.

Timeframe Analysis:

• Short-term (Hold): Neutral reading indicates near-term momentum has stalled as the stock consolidates
• Medium-term (Hold): Continued neutral signal suggests indecision in the intermediate timeframe as investors await catalysts
• Long-term (50% Buy): Moderate buy signal reflects underlying positive sentiment despite recent weakness

Trend Characteristics: The trend is showing Minimum strength and is Weakening, suggesting technical support is fragile heading into this earnings release and investors should prepare for potential volatility in either direction.

ANAB is currently trading at $53.92, positioned below its 5-day moving average of $54.68, below its 10-day average of $54.69, below its 20-day average of $55.79, below its 50-day average of $55.78, and below its 100-day average of $58.28. The stock remains above its 200-day moving average of $47.98, which provides long-term support but offers little comfort given the bearish short-term alignment.

The technical setup heading into earnings is cautionary, with the stock trading below all short- and intermediate-term moving averages and showing weakening momentum across multiple timeframes. The 200-day moving average at $47.98 represents critical long-term support, while resistance clusters around the $55-$58 zone where multiple moving averages converge. Given the high options-implied volatility of 70.83% and the stock's history of double-digit post-earnings moves, traders should expect significant price action regardless of whether results beat or miss estimates. The weakening technical picture suggests the stock may be vulnerable to further downside if earnings disappoint or if there's no positive news on the GSK litigation, while a strong beat or favorable legal update could trigger a sharp reversal given the heavily bullish analyst sentiment and substantial upside to price targets.